Inherited gene variations tied to treatment-related hearing loss in cancer patients
Cisplatin is one of the most widely used anti-cancer drugs and is a mainstay of treatment for children and adults with many types of brain and other solid tumors. …
Cisplatin is one of the most widely used anti-cancer drugs and is a mainstay of treatment for children and adults with many types of brain and other solid tumors. …
Patients who were told they had a 1-in-10 chance of winning $50 were more likely to complete home stool blood tests that help screen for colon cancer, according to a new study led by a researcher at the VA Ann Arbor Healthcare System and University of Michigan. The findings appear in a special issue of Annals of Internal Medicine…
Abl-kinase and leukemia Abl-kinase can turn “on” molecules that are involved in many cell functions including cell growth. In chronic myeloid leukemia, the chromosome that contains the gene for Abl-kinase swaps a section with another chromosome, causing what is known as the “Philadelphia chromosome.” When this mutation takes place in the blood stem cells in the bone marrow, Abl-kinase fuses with another protein, turning into a deregulated, hyperactive enzyme. This causes large numbers of blood-forming stem cells to grow into an abnormal type of white blood cell, which gives rise to chronic myeloid leukemia. To treat this type of leukemia we use drugs that specifically bind and block a part of Abl-kinase called the “active site.” As the name suggests, this is the part of the enzyme that binds molecules to turn them on. …
The new data, which builds on preliminary findings presented at the American Society of Hematology’s annual meeting in December 2013, include results from the first 25 children and young adults (ages 5 to 22) treated at the Children’s Hospital of Philadelphia and first five adults (ages 26 to 60) treated at the Hospital of the University of Pennsylvania. Twenty-seven of the 30 patients in the studies achieved a complete remission after receiving an infusion of these engineered “hunter” cells, and 78 percent of the patients were alive six months after treatment. “The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left,” said the study’s senior author, Stephan Grupp, MD, PhD, a professor of Pediatrics in Penn’s Perelman School of Medicine and director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia…
The first study, by Rena M. …
The results are good news for children and adolescents with Philadelphia chromosome-like ALL (Ph-like ALL), a subtype that until now was associated with a poor prognosis. …
There’s already enough evidence to justify increasing vitamin D levels to improve health, according to the opinion piece by Drs Michael F. Roizen of the Cleveland Clinic and Jeffrey D. Roizen of Children’s Hospital of Philadelphia. Meanwhile, they propose a randomized trial to conclusively determine whether vitamin D can reduce complication rates after surgery…
In December, the research team of Antonio Giordano, a pathologist, Director and Founder of the Sbarro Health Research Organization in Philadelphia, PA, and Professor of Pathology and Oncology at the University of Siena, Italy, published two separate studies aiming to address the urgent need to identify possible new methods for mesothelioma treatment. In the first study, published in the scientific journal Cell Cycle, Giordano’s researchers tested on mesothelioma cells the effect of two drugs designed to reactivate the p53 protein, one of the most important ‘tumor suppressors’, which is turned off in most human cancers. "In mesothelioma, although p53 is rarely mutated, it is inactivated by alterations in its pathway," says Francesca Pentimalli of the National Cancer Institute of Naples, Italy, lead author of the study. …
In the largest study of its kind, researchers led by the University of Pennsylvania School of Nursing have investigated the caregivers of 186 mothers to childhood brain tumor survivors aged 14-40 whose care needs last long into adulthood. They based their research on a model containing factors central to nursing practice, namely the caregiver, the survivor, and the family. They discovered that a complex interaction among components of the model, the health of the caregivers, the demands experienced by the caregiver, the caregiver’s perceptions about the health of the survivor, and the family’s support interact to explain how the caregiver assesses herself in her role. …
The high-risk variant was found in the GATA3 gene. …